Mylan was a global pharmaceutical company that developed, manufactured, and distributed generic, branded generic, and specialty pharmaceuticals. In November 2020, Mylan merged with Upjohn, a division of Pfizer, to form a new global healthcare corporation named Viatris Inc.. Prior to this merger, Mylan was one of the world’s largest producers of active pharmaceutical ingredients (APIs) and marketed more than 7,500 products in over 165 countries.

Core Business and Portfolio

Product Diversity:
The portfolio included prescription generics, branded generics, brand-name drugs, biosimilars, and over-the-counter (OTC) remedies.

Key Therapeutic Areas:
Mylan focused on oncology, immunology, endocrinology, dermatology, ophthalmology, respiratory, allergy, and psychiatric therapies.

Significant Products:
Notable products included the EpiPen (acquired in 2007), Wixela Inhub (a generic of Advair Diskus), and extensive antiretroviral (ARV) therapies, upon which more than 40% of people globally treated for HIV/AIDS depend.

Technological Expertise:
Through its subsidiary Mylan Technologies Inc. (MTI), the company specialized in transdermal patch technologies, medical-grade films, and adhesive laminates for medical devices.

Corporate History

Founding:
Established in 1961 by Milan Puskar and Don Panoz in White Sulphur Springs, West Virginia.

Manufacturing Milestones:
It received FDA approval for its first generic drug, Penicillin G tablets, in 1966.

Growth through Acquisitions:
Key acquisitions included Matrix Laboratories (2007) for API production, the generics division of Merck KGaA (2007), Abbott Laboratories’ non-U.S. developed markets business (2015), and Meda AB (2016).

Tax Inversion:
In 2014, the company moved its tax address to the Netherlands to benefit from lower corporate tax rates, while maintaining principal executive offices in the UK and a global center in Canonsburg, Pennsylvania.

Legal and Operational History

Regulatory Issues:
The company faced several FDA challenges, including a 2018 warning letter regarding its Morgantown, West Virginia facility, which eventually led to the cessation of manufacturing at that site in 2021.

Price Collusion & Litigation:
In December 2016, Mylan was accused by 20 state attorneys general of price-fixing schemes for generic drugs. More recently, in April 2025, the company reached a $335 million settlement with the New York Attorney General regarding its role in the opioid crisis.

Public Listing:
Mylan went public in 1973 and was listed on the NASDAQ (formerly ticker: MYL) and included in the S&P 500 index before the formation of Viatris.

Operations as Viatris
Since the merger, Mylan’s legacy operations are integrated into Viatris, which segments its business into Developed Markets (North America/Europe), Greater China, JANZ (Japan/Australia/New Zealand), and Emerging Markets. Viatris continues to market iconic brands such as Lipitor, Viagra, and Celebrex alongside Mylan’s original portfolio.